Data set: Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomide (TMZ).

Glioblastoma is the deadliest of all primary brain tumor with a very poor survival outcome. Alkylating agent such as temozolomide is used as a mainstay drug used in treating of glioblastoma patients including radiation, tumor treating field and surgery. However, this drug offers little to no benefit for the glioblastoma patients. Hence, the objective of the generation of this data is to understand and unravel genes that controls glioblastoma susceptibility and resistance to temozolomide using an unbiased genome scale CRISPR Cas9a knockout screen

Related Organizations

City University of New York
United States
King’s University
United States
Weill Cornell Medicine
United States
Cornell University
United States
York College, City University of New York
United States

Keywords

Dataset, CRISPR Cas9a , Glioblastoma, Cancer resistance, Chemotherapeutic resistance, Genome scale screen

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average